RENX.L - Renalytix AI plc

LSE - LSE Delayed Price. Currency in GBp
251.00
0.00 (0.00%)
At close: 4:36PM BST
Stock chart is not supported by your current browser
Previous Close251.00
Open250.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range244.10 - 250.00
52 Week Range85.00 - 334.00
Volume4,791
Avg. Volume43,698
Market Cap149.134M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-15.00
Earnings DateSep 3, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board

    NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr. Parikh is the Director of the Division of Nephrology and the Ronald Peterson Professor of Medicine at the Johns Hopkins School of Medicine. Dr. Parikh received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his internal medicine residency at the Nassau University Medical Center and SUNY at Stony Brook in New York, followed by his fellowship in Nephrology and Hypertension and UNOS Transplant Certification at the University of Colorado.

  • PR Newswire

    RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer

    NEW YORK, July 29, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the expansion of its leadership team with the appointment of diagnostic industry leader, Thomas McLain, as President and Chief Commercial Officer, effective immediately. In this non-board role, McLain will be responsible for leading the commercial program for KidneyIntelX ™, with a focus on establishing national and international clinical adoption and reimbursement.

  • Is Renalytix AI plc (LON:RENX) Trading At A 31% Discount?
    Simply Wall St.

    Is Renalytix AI plc (LON:RENX) Trading At A 31% Discount?

    Does the July share price for Renalytix AI plc (LON:RENX) reflect what it's really worth? Today, we will estimate the...

  • PR Newswire

    RenalytixAI Releases Positive Interim Results in Expanded Validation Study for KidneyIntelX™

    NEW YORK, July 9, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today positive interim analysis of data from the KidneyIntelX™ expanded validation study. The results show that in a multi-center cohort of Type 2 diabetes patients, the KidneyIntelX algorithm has met or exceeded required performance targets for identifying those patients experiencing rapid kidney function decline (RKFD)1 and patients who eventually progressed to kidney failure and/or dialysis.

  • PR Newswire

    U.S. CPT® Code Granted for KidneyIntelX™

    CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK , July 1, 2019 /PRNewswire/ --  Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled ...

  • PR Newswire

    Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

    NEW YORK, June 7, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that positive study results have been published in the Journal of Clinical Investigation (JCI) Insight1.  These results show FractalDx portfolio technology can accurately predict early acute kidney rejection in transplant patients. Early detection of acute transplant rejection is a critical unmet medical need that directly effects transplant success and long-term patient survival. In addition, the published results suggest that FractalDx can be used to personalize and potentially optimize the administration of immunosuppression therapy in kidney transplant patients.

  • PR Newswire

    RenalytixAI Expands Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

    NEW YORK, May 21, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio of advanced diagnostic and prognostic solutions in kidney transplant.

  • PR Newswire

    RenalytixAI and University Medical Center Groningen to Evaluate KidneyIntelX™ for Early Identification and Guiding Therapeutic Treatment of Diabetic Kidney Disease

    NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients with Type II Diabetes. The study will assess how effectively KidneyIntelX identifies patients with fast-progressing kidney disease who would be most likely to benefit from new drug therapies to prevent or slow down their progression to end-stage renal disease and dialysis. Hiddo J.L. Heerspink, Pharm.D., Department of Clinical Pharmacy and Pharmacology, UMCG and lead investigator in the planned evaluation said, "The ability of KidneyIntelX to discriminate fast-progressing kidney disease offers pharma the potential to enrich clinical trials with patients most likely to benefit most from novel drug therapies.

  • PR Newswire

    FDA Grants Breakthrough Device Designation to KidneyIntelX™

    NEW YORK, May 2, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), for its lead diagnostic, KidneyIntelX™. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company. KidneyIntelX is designed to diagnose and improve clinical management of patients with Type II diabetes with fast-progressing kidney disease, in an effort to curtail the estimated $114 billion annual cost1 of chronic and end-stage kidney disease to the United States healthcare system.

  • PR Newswire

    RenalytixAI Forms Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

    NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the formation of the core investigator group to support clinical and regulatory pathways for a portfolio of advanced diagnostic and prognostic solutions in kidney transplant known collectively as FractalDx. This follows the Company's announcement on January 2, 2019 that stated it had exercised its option from the Icahn School of Medicine at Mount Sinai ("ISMMS") for the exclusive license to technology and data underlying the FractalDx product portfolio.

  • PR Newswire

    RenalytixAI and AKESOgen In Joint Venture Partnership for Expanded Testing Capacity and Pharma Services

    NEW YORK , Feb. 13, 2019 /PRNewswire/ --  RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership ...

  • PR Newswire

    RenalytixAI Expands Leadership Team to Support Launch of AI-Enabled Diagnostics for Kidney Disease

    As vice president of clinical and scientific affairs, Connolly is leading RenalytixAI's recruitment efforts for the prospective clinical utility study for its lead diagnostic, KidneyIntelX, which is scheduled to start in Q4 2019. Connolly brings more than two decades of leadership experience in clinical research and development, the past ten years of which have focused on managing successful clinical trials as well as domestic and international regulatory affairs initiatives. Most recently, Connolly served as clinical services director at Pearl Pathways where she was responsible for all clinical services operations, the full-service contract research organization and the institutional review board.

  • PR Newswire

    RenalytixAI Initiates Clinical Validation Study of AI-Enabled KidneyIntelX™ for Diagnosing Fast-Progressing Kidney Disease

    Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators NEW YORK , Jan. 23, 2019 /PRNewswire/ --  Renalytix AI plc (LON: RENX), ...

  • PR Newswire

    RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease

    NEW YORK, Nov. 15, 2018 /PRNewswire/ -- Renalytix AI plc (LSE AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, has secured $29 million in funding to support the development and commercialization of two product categories for the early detection of kidney disease and accurate management of kidney transplant rejection. The Company intends to launch its first diagnostic product, KidneyIntelX™, in 2019 in collaboration with the Icahn School of Medicine at Mount Sinai, the medical school of the Mount Sinai Health System ("Mount Sinai").